Condition: Candidal Vulvovaginitis (ICD-10 Code: B37.3) · Vulvovaginal Candidiasis (VVC) · Sponsor: AVVA Pharmaceuticals Ltd.
This study aims to compare the efficacy and safety of the combination drug Clotrimazole+Lactulose with the monocomponent product Canesten® (clotrimazole) in adult women diagnosed with candidal vulvovaginitis. The primary objective was to confirm the superiority of the combination drug in terms of clinical and microbiological response on Day 25 of the study.
This description comes directly from the study's public registry record.
Sergey Tolmachev · +7 495 2690016 · tolmachev@rnd.avvapharma.com
Always discuss trial participation with your own doctor first.
| Healthcare Institution "1st Central District Polyclinic of the Central District of Minsk" | Minsk, Minsk City, Belarus | Recruiting |
| Healthcare Institution "14th Central District Polyclinic of the Partizansky District of Minsk" | Minsk, Belarus | Recruiting |
| Healthcare Institution "2nd Central District Polyclinic of the Frunzensky District of Minsk" | Minsk, Belarus | Recruiting |
| Healthcare Institution "4th City Polyclinic" of Minsk | Minsk, Belarus | Recruiting |
| Healthcare Institution "5th City Clinical Polyclinic" of Minsk | Minsk, Belarus | Recruiting |
| State Institution "Republican Center of Medical Rehabilitation and Balneotherapy" | Minsk, Belarus | Recruiting |
| SBI RR "Regional Clinical Skin and Venereal Dispensary" | Ryazan, Ryazan Oblast, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06835361